SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                  FORM 10-K/A


(Mark one)


   [ X ]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
          EXCHANGE ACT OF 1934
          For the fiscal year ended December 31, 1997

     or   

   [   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
          SECURITIES EXCHANGE ACT OF 1934

                         Commission File Number 0-15006
                         ------------------------------


                             T CELL SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

               Delaware                                  13-3191702
     (State or other jurisdiction of                  (I.R.S. Employer
     incorporation or organization)                  Identification No.)



                119 Fourth Avenue, Needham, Massachusetts 02194
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (781) 433-0771


        Securities registered pursuant to Section 12(b) of the Act: None

          Securities registered pursuant to Section 12(g) of the Act:
                         common stock, par value $.001


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing 
requirements for the past 90 days.

Yes X     No  
   ---       ---

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to 
this Form 10-K. [ ]

The aggregate market value of common stock held by non-affiliates as of 
March 2, 1998 was $48,115,239 (excludes shares held by directors and executive 
officers). Exclusion of shares held by any person should not be construed to 
indicate that such person possesses the power, direct or indirect, to direct
or cause the actions of the management or policies of the Registrant, or that
such person is controlled by or under common control with the Registrant.
The number of shares of common stock outstanding at March 2, 1998 was:
26,478,864 shares.

                      Documents Incorporated by Reference

Portions of the Registrant's Proxy Statement for the Annual Meeting of 
Stockholders to be held on May 12, 1998, are incorporated by reference into
Part III of this Form 10-K.



                                    PART III

Item 10.  DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The information under the Sections "Proposal 1--Election of Directors" and 
"Management" in the Registrant's Proxy Statement for the Annual Meeting of
Stockholders to be held on May 12, 1998, is hereby incorporated by 
reference.

Item 11.  EXECUTIVE COMPENSATION

The information under the Section "Management" of the Registrant's Proxy 
Statement for the Annual Meeting of Stockholders to be held on May 12, 1998,
is hereby incorporated by reference.

Item 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The information under the Section "Beneficial Ownership of Common Stock" of the 
Registrant's Proxy Statement for the Annual Meeting of Stockholders to be held
on May 12, 1998, is hereby incorporated by reference.

Item 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The information under the Sections "Proposal 1--Election of Directors" and
"Management" of the Registrant's Proxy Statement for the Annual Meeting of 
Stockholders to be held on May 12, 1998, is hereby incorporated by reference.




SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its 
behalf by the undersigned, thereunto duly authorized.

T CELL SCIENCES, INC.                             Date


By:  /s/ Una S. Ryan                              April 10, 1998
     -------------------------------------        
     Una S. Ryan
     President and Chief Executive Officer